Arecor and GSK collaborate to advance new vaccines

Published: 16-Jun-2011
Research & Development Finance Pharmaceutical

Agree to combine Arecor\'s formulation technologies with GSK\'s vaccines


Cambridge, UK-based biotech business Arecor has joined forces with pharmaceutical giant GlaxoSmithKline to develop advanced formulations of vaccines that will combine Arecor's Arestat formulation technologies with GSK's proprietary vaccines.

Arecor will receive unspecified payments on relevant development milestones and royalties on sales.

Tom Saylor, chief executive of Arecor, said: ‘The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK.’

Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilisation of biologics.

Arestat is a patented set of tools for stabilisation, which address the main pathways of degradation.

  • Companies:
  • GlaxoSmithKline
  • Arecor
See more

You may also like

Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

Read more
The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  3. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
Ingredients

Inhibrx milestone triggers payment to Arecor under license agreement

Under the terms of the license agreement, Arecor received an initial upfront payment from Inhibrx and is entitled to further payments on the achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation
Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: bepirovirsen for chronic hepatitis B

The hepatitis B virus causes both acute and chronic disease. Chronic hepatitis B can progress to complications including cirrhosis and liver cancer
Finance

Sareum notes completion of Sierra Oncology’s acquisition by GSK

Sareum Holdings, the specialist drug development company, notes that GSK has completed its acquisition of Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), for $1.9 billion in cash
Subscribe now